The SVP, Asia Pacific of Align Tech (NASDAQ: ALGN) is Selling Shares

Yesterday, the SVP, Asia Pacific of Align Tech (ALGNResearch Report), Julie Tay, sold shares of ALGN for $4.35M.

Following Julie Tay’s last ALGN Sell transaction on May 09, 2019, the stock climbed by 2.5%.

See today’s analyst top recommended stocks >>

Based on Align Tech’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $549 million and quarterly net profit of $71.85 million. In comparison, last year the company earned revenue of $437 million and had a net profit of $95.87 million. ALGN’s market cap is $25.61B and the company has a P/E ratio of 70.35. Currently, Align Tech has an average volume of 727.3K.

One of the top 25 analysts, according to, recently recommended Buy ALGN with a $350 price target. Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $336.17, reflecting a 3.2% upside.

In the last 30 days, insiders have sold $4.35M worth of ALGN shares and purchased $1.16M worth of ALGN shares. The insider sentiment on Align Tech has been neutral according to 52 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Align Technology, Inc. engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion.

Leave a Reply

Your email address will not be published. Required fields are marked *